🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#ThrowbackThursday 🚹💨 Water vapor therapy (Rezūm) shows promise for frail patients with #BPE and catheter dependency! ✅ 78.6% regained spontaneous voiding ✅ 91% remained catheter-free at 12 months ✅ Safe & minimally invasive in multimorbid patients A new option for those

#ThrowbackThursday 🚨 New insights from the STRIVE trial! 🚨 Enzalutamide + ADT cut the risk of progression or death by 76% vs bicalutamide in nmCRPC patients 💪 PSA progression risk also dropped by 82%! 🔥 Game changer for nmCRPC treatment! 🔗 [doi.org/10.1038/s41391…]

🎙️ Soon a deep dive with Prof. Alastair Lamb on the TRANSLATE trial — now published in The Lancet. How will these pivotal findings impact prostate cancer diagnosis? Stay tuned for our expert podcast episode. Alastair Lamb Cosimo De Nunzio #ProstateCancer #TRANSLATEtrial #Oncology

🎙️ New podcast episode coming soon! Dr. Lombardo interviews Dr. Elterman on First Interventional Treatment! #Urology #MedicalPodcast Don't miss it! 📷

The association between statin use, genetic variation, and prostate cancer risk nature.com/articles/s4139… This study investigated the relationship between statin use and #ProstateCancer risk, with a focus on potential genetic 🧬modifiers of this association. Using clinical and

#ThrowbackThursday 🧘‍♂️ Yoga boosts quality of life in men with localized #ProstateCancer! ➡️ 6 weeks of yoga improved sexual, physical, functional, and social wellbeing before surgery. 🦠 Plus, it enhanced immune response & reduced inflammation! 🔗 [doi.org/10.1038/s41391…]

🎙️ New podcast episode coming soon! Dr. Lombardo interviews Dr. Sunao Shoji about Focal Therapy using High-Intensity Focused Ultrasound with intraoperative prostate compression for patients with localized prostate cancer. A 7-year multi-center study you don’t want to miss!

📢 New study in Prostate Cancer and Prostatic Diseases 🥇First-ever head-to-head comparison: Rezūm vs. ThuLEP for BPH ≥80 mL 📈 ThuLEP: better Qmax and IPSS, but MCID for IPSS not reached 💦 Rezūm: better ejaculation rate, but more postoperative transient dysuria 🔗tinyurl.com/2ea6s7xw

🚨 Just published in The Lancet Oncology! 📌 The #TRANSLATEtrial shows that LATP biopsy detects more clinically significant prostate cancer than TRUS (60.1% vs 54.4%; OR 1.32, p=0.031). 🧬 Lower infection risk 📊 Comparable complications 😖 Slightly more pain reported 🔗

We are representing the Mexican Prostate Center 🇲🇽 at the American Urological Association Amer. Urol. Assn. anual meeting in Las Vegas, USA 🇺🇸 . We will have the great honor of participating in the panel of experts on benign prostatic growth. 🙌🏻 #holep #aeep #eep #AUA25 Hegel T-Santamaría

Our latest work in Prostate Cancer and Prostatic Diseases showing that black men initiating ADT for Advanced PC have better survival to white men. This has been also shown in mCRPC before but here also in hormone sensitivity adv disease Duke Urology DCI Center for Prostate & Urologic Cancers

🔬 New real-world study on #BPH surgeries! Outpatient TURP, GreenLight PVP, and UroLift PUL show 📉 low med use after 1 year (lowest with PUL 🚀). Still, about 10% of patients stayed on meds 💊 even 5 years after surgery! #Urology #BPH #Health READ MORE HERE 👉

🚨 New Podcast Episode Alert! COMING SOON! 🎙️ Dr. Lombardo interviews Dr. Ravi on the crucial topic of Evaluation of Clinical Risk Stratification to determine the benefit of long-term vs. short-term androgen deprivation in high-risk localized prostate cancer. Tune in now!

Exciting AUA25 congress at Las Vegas! Many ground-breaking abstracts cutting the edge of Prostate cancer and Prostatic diseases! Future is now! Amer. Urol. Assn. #AUA25 #urosome

🔬 Gleason grading for #ProstateCancer is powerful but subjective. 💻 We trained a ViT-based AI model to diagnose 🧠 and grade tumors from histology images (TMA + WSI)! ✅ High accuracy and strong external validation show real potential for digital pathology. #AI #Cancer

❌Zoledronic acid (ZA) adds no benefit to enzalutamide + ADT in mHSPC, per phase II BonEnza trial: ⚖️ Bone ORR: 70% in both arms ⏳ No PFS or OS advantage 🧲 Whole body-MRI proved a reliable tool to assess bone response! OncoAlert Prostate Cancer Foundation Advanced Prostate Cancer Consensus Conference nature Prostate Cancer and Prostatic Diseases

🎯 Hypofractionated radiotherapy is safe and effective for elderly (≥75 yrs) patients with localized #ProstateCancer! 📈 5-year survival: ✅ 95.6% Overall ✅ 99.2% Cancer-specific ✅ 97.3% Metastasis-free 👴🏼 Radiotherapy plays a key role in fit elderly patients! #Oncology

🧬 In high-risk #ProstateCancer BCR patients, enzalutamide ± leuprolide 📈 improved metastasis-free survival vs leuprolide alone! 🛡️ Results consistent with EMBARK trial. 🤝 Shared decision-making remains key for tailored treatment. #Oncology #CancerResearch #Urology more

Alea iacta est! 🎲 Are MISTs ready to replace meds & TURP as first-line for BPH? Not quite yet. Challenges in cost, equity & evidence remain. But the shift has started! 💥 Find more on: 🔗 rdcu.be/eoVSY

🔬 NEW WEBINAR ON #SIUACADEMY🔬 Join Dr Cosimo De Nunzio and expert faculty for a deep dive into the latest breakthroughs in metastatic prostate cancer treatment. Explore next-generation imaging, precision medicine, and advances in personalized care. Stay ahead of the latest